Drugs / DH001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06092606 | Apr 2023 → Jan 2025 | cancer, cardiac rhythm disease, doxorubicin induced cardiomyopathy, heart failure +1 | Monyan Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DH001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06092606 ↗ |